Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01328444 · ClinicalTrials.gov registry record · Phase 3
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 349
- Enrollment target
NCT01328444 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 349 participants.
The verdict
NCT01328444, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 349 participants
- Enrollment target
Study Summary
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily administration of GSK573719/GW642444 Inhalation Powder (125/25mcg and 62.5/25mcg), GSK573719 Inhalation Powder (125mcg and 62.5mcg), GW642444 Inhalation Powder 25 mcg and placebo delivered by a Novel dry powder inhaler (Novel DPI)
Interventions
- DRUG GW642444 25
- DRUG GSK 573719 +GW642444 125/25
- DRUG GSK573719 + GW642444 62.5/25
- DRUG GSK 573719 125
- DRUG GSK 573719 62.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 349 participants |
| Start Date | 2011-03-01 |
| Est. Completion | 2012-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01328444
The ClinicalTrials.gov registry entry for NCT01328444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 349 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which GW642444 25 is the first listed.
NCT01328444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01328444 about?
NCT01328444 is a clinical study titled "An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A". This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444. The primary objective is to evaluate lung function and exercise endurance time after 12 weeks of once-daily adminis...
What is the current status of trial NCT01328444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 349 participants. The study started on 2011-03-01. Estimated completion is 2012-06-14.
What interventions are being tested in trial NCT01328444?
The interventions under investigation include: GW642444 25 (DRUG), GSK 573719 +GW642444 125/25 (DRUG), GSK573719 + GW642444 62.5/25 (DRUG), GSK 573719 125 (DRUG), GSK 573719 62.5 (DRUG).
Who is sponsoring clinical trial NCT01328444?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.